NCT00884182已完成2 期
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 350
- 试验地点
- 13
- 主要终点
- To provide information concerning the safety of the Split Virion Pandemic Influenza vaccine.
研究概览
简要总结
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic.
Study objectives:
- To describe the safety profiles in the periods following each vaccination in subjects receiving different vaccination schedule.
- To describe the immune response after each vaccination in subjects receiving study vaccine.
详细描述
Study participants will receive two administrations of the investigational vaccine at one of 3 vaccination schedules.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All Subjects
- •Subject and parent(s)/legal representative able to attend all scheduled visits and to comply with all trial procedures.
- •Completion of vaccination according to the national immunization schedule
- •Subjects Aged ≥ 2 Years to < 18 Years:
- •Aged ≥ 2 years to < 18 years on the day of inclusion.
- •Provision of Informed Consent Form signed by the subject's the parent(s)/legal representative (and by an independent witness if required by local regulations). In addition, provision of Assent Form signed by subjects aged 8 to 11 years, and of Informed Consent Form signed by subjects ≥ 12 years.
- •For a female of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination.
- •Subjects Aged ≥ 6 Months to < 2 Years:
- •Aged ≥ 6 months to < 2 years on the day of inclusion.
- •Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg.
- •Provision of Informed Consent Form signed by the parent(s) or other legal representative (and by an independent witness if required by local regulations).
排除标准
- •All subjects
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- •Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
- •Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
- •Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
- •Receipt of Blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
- •Receipt of any vaccine in the 4 weeks preceding trial vaccination
- •Planned receipt of any vaccine in the 4 weeks following any trial vaccination
- •(Known) Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen or Hepatitis C seropositivity
- •Previous vaccination against avian influenza with either the trial vaccine or another vaccine
- •Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
- •Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- •Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw
- •Subjects Aged ≥2 Years to <18 Years:
- •For a female of child-bearing potential, known pregnancy or positive urine pregnancy test
- •Breast-feeding female
- •Febrile illness (temperature ≥ 37.5 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment
- •Subjects Aged ≥ 6 Months to < 2 Years:
- •History of seizures
- •Febrile illness (temperature ≥ 38 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
研究组 & 干预措施
Group 3
Experimental
Participants on vaccination schedule 3 (Day 0 and Day 42)
干预措施: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine (Biological)
Group 1
Experimental
Participants on vaccination schedule 1 (Day 0 and Day 21)
干预措施: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine (Biological)
Group 2
Experimental
Participants on vaccination schedule 2 (Day 0 and Day 14)
干预措施: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine (Biological)
结局指标
主要结局
To provide information concerning the safety of the Split Virion Pandemic Influenza vaccine.
时间窗: 21 days post-vaccination and entire study
次要结局
- To provide information concerning the immunogenicity of Split Virion Pandemic Influenza vaccine.(21 days post-vaccination)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in AdultsOrthomyxoviridae InfectionsInfluenzaNCT00545701Sanofi Pasteur, a Sanofi Company100
已完成
1 期
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused DiarrheaCampylobacter InfectionNCT02067676U.S. Army Medical Research and Development Command48
已完成
1 期
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077InfluenzaNCT00402649National Institute of Allergy and Infectious Diseases (NIAID)35
已完成
3 期
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™Infections, StreptococcalNCT00678301GlaxoSmithKline365
已完成
3 期
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeInfections, RotavirusNCT00533507GlaxoSmithKline230